ADVANCES IN PSORIASIS TREATMENT: COMBINING SECUKINUMAB WITH PHOTOTHERAPY
Keywords:
Psoriasis, secukinumab, biologics, phototherapy, narrowband UVB, IL-17 inhibitor, combination therapy, PASI improvement, moderate to severe psoriasis, skin clearance.Abstract
This article explores the benefits of combining secukinumab, a biologic IL-17 inhibitor, with narrowband UVB phototherapy in treating moderate to severe psoriasis. It presents findings from five patients who demonstrated significant skin clearance and improved quality of life through this combination approach, suggesting that it can be an effective treatment for resistant forms of the disease
References
1. Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. Journal of the American Academy of Dermatology 2008.
2. McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. The New England Journal of Medicine. 2011.
3. Wang Y, Zhang Z, Wang Y, et al. Efficacy of secukinumab in patients with moderate to severe psoriasis: a systematic review and meta-analysis. Dermatology. 2018.
4. Lowes MA, Suárez-Fariñas M, Krueger JG. Immunology of Psoriasis Annual Review of Immunology. 2014
5. Nickoloff BJ, Nestle FO. Recent insights into the immunopathogenesis of psoriasis provide new therapeutic opportunities. The Journal of Clinical Investigation. 2004.
6. Griffiths CE, Barker JN. Pathogenesis and clinical features of psoriasis. Lancet. 2007.
7. Boehncke WH, Schon MP. Psoriasis. Lancet. 2015.
8. U.S.Department of Health and Human Services. Psoriasis. National Institutes of Health. 2016.
9. Gelfand JM, Weinstein R, Porter S, et al. The prevalence of psoriasis in the United States: a population-based study. Archives of Dermatology. 2005.
10. Dalgard FJ, Gieler U, Tomas-Aragones L, et al. The psychological burden of skin diseases: a cross-sectional study. Journal of Investigative Dermatology. 2015.
11. Lowes MA, Suárez-Fariñas M, Krueger JG. Immunology of Psoriasis Annual Review of Immunology. 2014.
12. Egeberg A, Mozaffarian N, Thyssen JP, et al. The cost-effectiveness of secukinumab compared with ustekinumab for the treatment of moderate to severe psoriasis. Journal of the European Academy of Dermatology and Venereology. 2017.
13. McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. The New England Journal of Medicine. 2011.
14. Dall'Oglio F, et al. Efficacy of narrowband UVB phototherapy in the treatment of psoriasis: a systematic review and meta-analysis International Journal of Dermatology. 2019.
15. Bergler-Czop B, et al. The role of phototherapy in the treatment of psoriasis: A review. Advances in Dermatology and A/lergology. 2019.
16. Menter A, et al. Secukinumab: a new therapy for moderate to severe psoriasis. Journal of Drugs in Dermatology. 2016.
17. Griffiths CE, Barker JN. Pathogenesis and clinical features of psoriasis. Lancet. 2007
18. Menter A, et al. Guidelines of Care for the Management of Psoriasis and Psoriatic Arthritis: Section 3. Phototherapy. Journal of the American Academy of Dermatology. 2008
19. World Health Organization. Global report on psoriasis. 2016
20. McKinnon L, et al. The Role of Narrowband UVB Phototherapy in the Treatment of Psoriasis: A Clinical Perspective. Journal of Dermatological Treatment. 2020
21. McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. The New England Journal of Medicine. 2011.
22. Papp KA, et al. Secukinumab for the Treatment of Moderate to Severe Psoriasis: A Review of Clinical Efficacy and Safety. Journal of Drugs in Dermatology. 2016.
23. World Health Organization. Global report on psoriasis. 2016.
24. Gelfand JM, et al. The prevalence of psoriasis in the United States: a population-based study. Archives of Dermatology. 2005